Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02272764
Recruitment Status : Completed
First Posted : October 23, 2014
Last Update Posted : December 12, 2014
Sponsor:
Information provided by (Responsible Party):
Alkermes, Inc.

Brief Summary:
This study will evaluate the impact of Itraconazole on the pharmacokinetics of ALKS 5461.

Condition or disease Intervention/treatment Phase
Pharmacokinetics Drug: Itraconazole Drug: ALKS 5461 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of the Effects of Itraconazole on the Pharmacokinetics of ALKS 5461 in Healthy Volunteers
Study Start Date : October 2014
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Itraconazole
Itraconazole or placebo
Drug: Itraconazole
Administered orally in a crossover design
Other Name: Itraconazole or placebo

Experimental: ALKS 5461
ALKS 5461 or placebo Sublingual tablet
Drug: ALKS 5461
Administered sublingually in a crossover design
Other Name: ALKS 5461 or placebo




Primary Outcome Measures :
  1. Drug-Drug Interaction - AUC0-t [ Time Frame: Up to 48 hours ]
    Area under the concentration time curve from time zero to the last measureable time point (AUC0-t) of ALKS 5461 in the presence and absence of itraconazole

  2. Drug-Drug Interaction - AUC0-inf [ Time Frame: Up to 48 hours ]
    Area under the concentration time curve from time zero to infinity (AUC0-inf) of ALKS 5461 in the presence and absence of itraconazole

  3. Drug-Drug Interaction - Cmax [ Time Frame: Up to 48 hours ]
    Maximum plasma concentration (Cmax) of ALKS 5461 in the presence and absence of itraconazole


Secondary Outcome Measures :
  1. Safety and tolerability will be measured by incidence of adverse events [ Time Frame: Up to 32 Days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Has a body mass index (BMI) of 18.0 - 30.0 kg/m2
  • Is in good physical health
  • Agrees to use an approved method of contraception for the duration of the study
  • Additional criteria may apply

Exclusion Criteria:

  • Has current evidence, or history of any clinically significant medical or psychiatric condition or observed abnormality
  • Is currently pregnant or breastfeeding
  • Has a history of or current infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus (HIV)
  • Has a lifetime history of opioid abuse or dependence
  • Has current abuse or dependence on alcohol or any drugs
  • Has used nicotine within 90 days prior to randomization
  • Additional criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02272764


Locations
Layout table for location information
United States, Kansas
Alkermes Investigational Site
Overland Park, Kansas, United States, 66212
Sponsors and Collaborators
Alkermes, Inc.
Investigators
Layout table for investigator information
Study Director: Sanjeev Pathak, MD Alkermes, Inc.

Layout table for additonal information
Responsible Party: Alkermes, Inc.
ClinicalTrials.gov Identifier: NCT02272764     History of Changes
Other Study ID Numbers: ALK5461-214
First Posted: October 23, 2014    Key Record Dates
Last Update Posted: December 12, 2014
Last Verified: December 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Itraconazole
Hydroxyitraconazole
Naltrexone
Buprenorphine
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists
Alcohol Deterrents